ClinicalTrials.Veeva

Menu

Evaluation of Vaccinal and Natural Immunity Against Meningococcus C

U

University Hospital, Clermont-Ferrand

Status

Completed

Conditions

Prevention of Meningococcus C Infections

Treatments

Other: Meningococcus C conjugate vaccine

Study type

Interventional

Funder types

Other

Identifiers

NCT02844088
CHU-0273
2015-A01437-42 (Other Identifier)

Details and patient eligibility

About

Meningococcus C vaccine was first used in France to prevent epidemics. It was a success in Puy-de-Dôme, Landes, Pyrénées Atlantiques and Hautes Pyrénées. Following many European countries, France introduced meningococcus C conjugate vaccine in 2009 but this recommendation was not suffiicently applied (6,6% of the 20-25 years-old were vaccinated in 2015).

The situation in France is very different from UK and there is no data on the subject. The vaccination campaign in 2002 in Puy-de-Dôme offers much more detachment, possible comparison between vaccinated and unvaccinated people, among which meningococcus circulation could maintain immunity. This is the reason why we have decided to assess in 2016 the vaccinal and natural immunity among Puy-de-Dôme population.

Full description

People were recruited during hospitalisation or consultation of Pediatric, Occupational Medecine, Infectiology departments of Clermont Ferrand Hospital or Health Service of Auvergne's University, from March to September 2016.

Doctors gave informations about the study and collected consents before blood tests were done (two tubes of 4,5mL each).

Blood tests were daily collected and freezed. Then they were analysed at Meningococcus National Reference Center, in Paris.

Enrollment

184 patients

Sex

All

Ages

13 to 39 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

    • people from 13 to 39 years old
  • who received meningococcus C conjugate vaccine in 2002 in Puy-de-Dôme (vaccinated group) or not (unvaccinated group)

Exclusion criteria

  • vaccination before or after 2002 containing meningococcus C valence
  • refusal to participate

Trial design

Primary purpose

Prevention

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

184 participants in 2 patient groups

vaccinated group
Experimental group
Description:
evaluation of immunity's level against meningococcus C among people vaccinated in 2002 in Puy-de-Dôme
Treatment:
Other: Meningococcus C conjugate vaccine
unvaccinate group
Other group
Description:
Duration of vaccinal immunity, compare vaccinal immunity to possible natural immunity among unvaccinated people
Treatment:
Other: Meningococcus C conjugate vaccine

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems